Recall accuracy for the symptoms of a major depressive episode among clinical trial participants

Boadie W. Dunlop, Maria Granros, Amber Lechner, Tanja Mletzko-Crowe, Charles Nemeroff, Helen S. Mayberg, W. Edward Craighead

Research output: Contribution to journalArticle

Abstract

For patients with major depressive disorder (MDD), approaches to treatment differ for those with a single versus recurrent episodes. Based on studies of community samples, however, accuracy is low for identifying past episodes. Recall accuracy among clinical samples with a well-defined major depressive episode (MDE) has not been examined previously. We evaluated episode recall accuracy in 79 MDD patients in follow-up of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study at 12- and 24-month time-points after starting treatment. Using the Structured Clinical Interview for DSM-IV, patients were asked to recall whether they had been experiencing the nine criterion symptoms of an MDE at the time of their intake assessment. Accuracy of recall for the index MDE was high, with 95% of patients at month 12 and 85% at month 24 recalling sufficient symptoms to meet the diagnostic criteria. Recall accuracy for specific symptoms varied considerably, from >90% for dysphoria and anhedonia, to 55% for psychomotor and weight/appetite changes. For the thoughts of death/suicide criterion, patients with erroneous recall were significantly more likely to recall having had the symptom at the intake evaluation (though they had denied it at the time) than vice versa (p <.007). Patients who have participated in a clinical trial are likely to recall accurately a past MDE up to two years prior. Optimal vigilance for suicidal ideation for treatment-naïve patients should include a combination of self-report and clinician assessments.

Original languageEnglish (US)
Pages (from-to)178-184
Number of pages7
JournalJournal of Psychiatric Research
Volume116
DOIs
StatePublished - Sep 1 2019
Externally publishedYes

Fingerprint

Clinical Trials
Major Depressive Disorder
Depression
Anhedonia
Suicidal Ideation
Appetite
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Self Report
Suicide
Interviews
Weights and Measures

Keywords

  • Anhedonia
  • Antidepressant
  • CBT
  • Depression
  • Dysphoria
  • Suicide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. / Dunlop, Boadie W.; Granros, Maria; Lechner, Amber; Mletzko-Crowe, Tanja; Nemeroff, Charles; Mayberg, Helen S.; Craighead, W. Edward.

In: Journal of Psychiatric Research, Vol. 116, 01.09.2019, p. 178-184.

Research output: Contribution to journalArticle

Dunlop, Boadie W. ; Granros, Maria ; Lechner, Amber ; Mletzko-Crowe, Tanja ; Nemeroff, Charles ; Mayberg, Helen S. ; Craighead, W. Edward. / Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. In: Journal of Psychiatric Research. 2019 ; Vol. 116. pp. 178-184.
@article{14aa618bc54944f8b06e85d619e1e76f,
title = "Recall accuracy for the symptoms of a major depressive episode among clinical trial participants",
abstract = "For patients with major depressive disorder (MDD), approaches to treatment differ for those with a single versus recurrent episodes. Based on studies of community samples, however, accuracy is low for identifying past episodes. Recall accuracy among clinical samples with a well-defined major depressive episode (MDE) has not been examined previously. We evaluated episode recall accuracy in 79 MDD patients in follow-up of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study at 12- and 24-month time-points after starting treatment. Using the Structured Clinical Interview for DSM-IV, patients were asked to recall whether they had been experiencing the nine criterion symptoms of an MDE at the time of their intake assessment. Accuracy of recall for the index MDE was high, with 95{\%} of patients at month 12 and 85{\%} at month 24 recalling sufficient symptoms to meet the diagnostic criteria. Recall accuracy for specific symptoms varied considerably, from >90{\%} for dysphoria and anhedonia, to 55{\%} for psychomotor and weight/appetite changes. For the thoughts of death/suicide criterion, patients with erroneous recall were significantly more likely to recall having had the symptom at the intake evaluation (though they had denied it at the time) than vice versa (p <.007). Patients who have participated in a clinical trial are likely to recall accurately a past MDE up to two years prior. Optimal vigilance for suicidal ideation for treatment-na{\"i}ve patients should include a combination of self-report and clinician assessments.",
keywords = "Anhedonia, Antidepressant, CBT, Depression, Dysphoria, Suicide",
author = "Dunlop, {Boadie W.} and Maria Granros and Amber Lechner and Tanja Mletzko-Crowe and Charles Nemeroff and Mayberg, {Helen S.} and Craighead, {W. Edward}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jpsychires.2019.03.008",
language = "English (US)",
volume = "116",
pages = "178--184",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recall accuracy for the symptoms of a major depressive episode among clinical trial participants

AU - Dunlop, Boadie W.

AU - Granros, Maria

AU - Lechner, Amber

AU - Mletzko-Crowe, Tanja

AU - Nemeroff, Charles

AU - Mayberg, Helen S.

AU - Craighead, W. Edward

PY - 2019/9/1

Y1 - 2019/9/1

N2 - For patients with major depressive disorder (MDD), approaches to treatment differ for those with a single versus recurrent episodes. Based on studies of community samples, however, accuracy is low for identifying past episodes. Recall accuracy among clinical samples with a well-defined major depressive episode (MDE) has not been examined previously. We evaluated episode recall accuracy in 79 MDD patients in follow-up of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study at 12- and 24-month time-points after starting treatment. Using the Structured Clinical Interview for DSM-IV, patients were asked to recall whether they had been experiencing the nine criterion symptoms of an MDE at the time of their intake assessment. Accuracy of recall for the index MDE was high, with 95% of patients at month 12 and 85% at month 24 recalling sufficient symptoms to meet the diagnostic criteria. Recall accuracy for specific symptoms varied considerably, from >90% for dysphoria and anhedonia, to 55% for psychomotor and weight/appetite changes. For the thoughts of death/suicide criterion, patients with erroneous recall were significantly more likely to recall having had the symptom at the intake evaluation (though they had denied it at the time) than vice versa (p <.007). Patients who have participated in a clinical trial are likely to recall accurately a past MDE up to two years prior. Optimal vigilance for suicidal ideation for treatment-naïve patients should include a combination of self-report and clinician assessments.

AB - For patients with major depressive disorder (MDD), approaches to treatment differ for those with a single versus recurrent episodes. Based on studies of community samples, however, accuracy is low for identifying past episodes. Recall accuracy among clinical samples with a well-defined major depressive episode (MDE) has not been examined previously. We evaluated episode recall accuracy in 79 MDD patients in follow-up of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study at 12- and 24-month time-points after starting treatment. Using the Structured Clinical Interview for DSM-IV, patients were asked to recall whether they had been experiencing the nine criterion symptoms of an MDE at the time of their intake assessment. Accuracy of recall for the index MDE was high, with 95% of patients at month 12 and 85% at month 24 recalling sufficient symptoms to meet the diagnostic criteria. Recall accuracy for specific symptoms varied considerably, from >90% for dysphoria and anhedonia, to 55% for psychomotor and weight/appetite changes. For the thoughts of death/suicide criterion, patients with erroneous recall were significantly more likely to recall having had the symptom at the intake evaluation (though they had denied it at the time) than vice versa (p <.007). Patients who have participated in a clinical trial are likely to recall accurately a past MDE up to two years prior. Optimal vigilance for suicidal ideation for treatment-naïve patients should include a combination of self-report and clinician assessments.

KW - Anhedonia

KW - Antidepressant

KW - CBT

KW - Depression

KW - Dysphoria

KW - Suicide

UR - http://www.scopus.com/inward/record.url?scp=85067880398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067880398&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2019.03.008

DO - 10.1016/j.jpsychires.2019.03.008

M3 - Article

C2 - 30878146

AN - SCOPUS:85067880398

VL - 116

SP - 178

EP - 184

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -